Policy
FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
What's New: Drugs RSS Feed · By FDA ·
The Brief
- The FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech) with carboplatin and pemetrexed.
- The approval covers first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.
- The FDA announcement is dated 2026-11-07 in the source feed, but the approval itself is dated March 1, 2024.
Why it matters
It gives a first-line targeted treatment option, combined with standard chemotherapy, for a subset of lung cancer patients with EGFR exon 20 insertion mutations. Readers covering oncology should note the approval date given in the source differs from the feed date.
Who’s affected
- Patients with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations
- Oncologists treating NSCLC with EGFR exon 20 insertion mutations
On March 1, 2024, the FDAapproved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion…
Timeline
FDA approves amivantamab-vmjw (Rybrevant) with carboplatin and pemetrexed for first-line EGFR exon 20 insertion-mutated NSCLC
What's New: Drugs RSS Feed
FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications